Mikhail Blagosklonny is a well-known scientist in the field of medicine and research. The Russian scientist has established himself as an expert in aging and cancer therapies. He also holds a position of professor at Roswell Park Cancer Institute in the field of Oncology.
He is also an editor of some journals that talk about the dreaded disease, cancer. After completing high school, he went to St. Petersburg, First Pavlov State Medical University and successfully graduated with an M.D. in Internal Medicine.
Afterward, he went to do a doctorate in experimental medicine and also studied cardiology, fields which made him acquire the knowledge required in carrying out research. He commenced his successful career when he was appointed as an associate professor of medicine at New York Medical College.
He continued to excel as he went to Ordway Research Institute where Mikhail works as a senior scientist until 2009 when he joined another coveted institution called Roswell Park Cancer Insitute. Joining this organization is a dream come true because it is dedicated to helping cancer patients, a field that Mikhail is interested. View Mikhail’s profile on Google Scholar
Many know Mikhail Blagosklonny from is the ability to formulated hypothesis that has the focus on the possible discovery of cancer drug and prevention of aging. It is a theory that is based on what Mikhail beliefs that TOR signaling has a primary role in cancer and aging process.
It is an idea that has made scientist dig deeper into the issue. He has a lot of interest in the Rapamycin drug which has a lot of possibility of curing cancer. Mikhail Blagosklonny has also authored some books that have been of help to his students and other researchers. From his research, he has published a lot of journals and other papers regarding the field of Oncology.
He is the current editor-in –chief of Cell Cycle, Aging, and Oncortaget. He is also a board member of Cell and Death. He takes many positions being a talented researcher. He works as an associate editor of Cancer Biology and Therapy. Mikhail Blagosklonny has worked hard to see the ratings of Oncotarget improve. There is also an increase in the number of people in the medical field that are reading the journal.